COH 2/02

Atty. Docket No. 22253-70421 [204648]

PATENT

3,4,39,40,42,44,+46

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1. (Withdrawn) A purified cancer-linked protein kinase, Hunk.
- 2. (Withdrawn) The purified protein of claim 1, comprising the amino acid sequence set forth in SEQID No. 2.
- 3. (Currently Amended) An The isolated nucleotide sequence comprising the nucleotide sequence set forth in SEQID No: 1 encoding the kinase of claim 1.
- 4. (Currently Amended) The isolated nucleotide sequence of claim 3, consisting of comprising the nucleotide sequence set forth in SEQID No:1.
- 5 (Withdrawn) A method of delivering the kinase of claim 1 to a target cell, wherein the method comprises delivering to the target cell an effective amount of the kinase.
- 6. (Withdrawn) The method of delivering the kinase of claim 3 to a target cell, wherein the method comprises delivering to the target cell an effective amount of the nucleotide sequence encoding the kinase.
- (Withdrawn) A method of delivering a therapeutically effective amount of the kinase of claim 1 to a target cell in a patient in need of such kinase, wherein the method comprises delivering to the patient a therapeutically effective amount of the kinase of claim 1.
- 8. (Withdrawn) A method of delivering a therapeutically effective amount of the kinase of claim 3 to a target cell in a patient in need of such kinase, wherein the

Mulsikale

- 34. (Withdrawn) The method of claim 32, wherein the modulated activity comprises an activation of the kinase, or an overexpression or a measurable increase in kinase activity.
- 35. (Withdrawn) The method of claim 32, wherein the modulated activity comprises transformation of the target cell.
- 36. (Withdrawn) The method of claim 32, wherein the compound comprises one or more compositions.
- 37. (Withdrawn) A method of using the kinase of claim 1 as a prognostic tool in a patient, wherein the method comprises detecting the presence of the kinase as a molecular marker in the patient to predict the behavior of a tumor, cancer, carcinoma, sarcoma, neoplasm, leukemia, lymphoma or hyperproliferative cell disease or oncogene expression in the patient, and applying that detection to predict the appropriate therapy for the patient to treat the tumor, cancer, carcinoma, sarcoma, neoplasm, leukemia, lymphoma or hyperproliferative cell disease or oncogene expression.
- 38. (Withdrawn) A method of using the kinase of claim 1 as a prognostic tool in a patient, wherein the method comprises measuring the activity or change in activity of the kinase as a molecular marker in the patient to predict the behavior of a tumor, cancer, carcinoma, sarcoma, neoplasm, leukemia, lymphoma or hyperproliferative cell disease or oncogene expression in the patient, and applying that measurement to predict the appropriate therapy for the patient to treat the tumor, cancer, carcinoma, sarcoma, neoplasm, leukemia, lymphoma or hyperproliferative cell disease or oncogene expression.
- 39. (Original) A recombinant cell comprising the isolated nucleic acid of claim 3.
 - 40. (Original) A vector comprising the isolated nucleic acid of claim 3.

- (Withdrawn) An antibody specific for the polypeptide of claims 1, and 41. homologues, analogs, derivatives or fragments thereof having Hunk activity.
- 42. (Currently Amended) An isolated nucleic acid sequence comprising a sequence complementary to all or part of the nucleic acid sequence of claim 3, and to mutants, derivatives, homologues or fragments thereof encoding a protein cell having Hunk-activity. Stated?
 - (Cancelled)
- (Currently Amended) A mammalian cell comprising the recombinant 44. isolated nucleic acid according to claim 42.
 - (Withdrawn) A transgenic cell comprising the protein according claim 1.
- (Original) The isolated nucleic acid of claim 3, further comprising a 46. reporter gene operably fused thereto, or a fragment thereof having reporter activity.
- (Withdrawn) A transgenic animal comprising a transgene comprising an 47. isolated nucleic acid of claim 3.